Novartis’ Pluvicto radioligand therapy faces an EU setback risk after the company withdrew an application to expand the label into earlier prostate cancer treatment, despite having U.S. and UK approvals for the same indication. In the field, competitors and payers will view the decision as a signal of how regional regulatory and benefit-risk judgments can diverge. Separately, a radioligand market dynamic emerged as the pathway toward generic competition draws nearer, with commentary pointing to a rival’s intent to bring the first generic into a market long dominated by Novartis. Together, the items reflect both label strategy recalibration and the long-anticipated shift toward cost pressure. For biotech stakeholders, these developments underscore the need to monitor EU filing strategy and to assess how competitive filings could affect pricing and market access in radioligand oncology.